differentiating induced neural progenitor cells into astrocytes

Differentiating Induced Neural Progenitor Cells into Astrocytes

Change the medium to neuro-diff-medium when the cells are approximately 70% confluent and continue to change the medium every other day for three weeks. Do not split the cells during differentiation. After three weeks, cells should express the neuronal marker TuJ1.
To gain more mature neurons and neuronal subtypes, continue differentiation up to three months. For differentiation of iNPCs specifically towards a glial lineage, change the medium to glial induction medium, including 20 nanograms per milliliter of epidermal growth factor to induce differentiation into glial precursor cells. Remove half of the medium and replace with fresh medium every other day for about two weeks.
During this period, cells should be split 1 to 3 in the presence of 10 micromolar Rho-kinase inhibitor when 100% confluency is reached. After two weeks, differentiate the cells further into astrocytes by changing the medium to commercially available astrocyte medium when the cells are nearly confluent and by continuing to change the medium every second day. Approximately seven days later, cells start to express astrocyte markers.

differentiating-induced-neural-progenitor-cells-into-astrocytes

Nanyang Technological University

Research

JoVE Encyclopedia of Experiments

Neuroscience

Neuronal Culture Techniques

Advanced Neuronal Models

EoE Sub Articles

eoe sub articles

1. Differentiation of iNPCs
<ol>
	<li>Differentiation towards neuronal lineage&#8203;
	<ol>
		<li>Culture cells on laminin-coated plates as described above. Change media to neuro-diff-media (DMEM/F-12, 1x N2, 1x B27, 300 ng/ml cAMP, 200 &#181;M vitamin C, 10 ng/ml BDNF, 10 ng/ml GDNF) when cells are approximately 70% confluent. Change media every other day for three weeks. Do not split cells during differentiation.</li>
		<li>After three weeks, cells should express the neuronal marker TUJ1. To gain more mature neurons and neuronal subtypes, continue differentiation upto 3 months.</li>
	</ol>
	</li>
	<li>Differentiation towards glial lineage
	<ol>
		<li>Change media to glial induction media (1:1 DMEM/F-12 : Neurobasal, 1x N2, 1x B27, 10 &#181;M &#946;-mercaptoethanol, 100 &#181;M non-essential amino acids, 1.5 mM L-Glutamine, 5 &#181;g/ml insulin, 40 ng/ml T3) including 20 ng/ml EGF to induce differentiation into glial precursor cells. Remove half of the media and replace with fresh media every other day for about 2 weeks. During this period, cells should be split 1:3 in the presence of 10 &#181;M ROCK inhibitor Y27632 when 100% confluency is reached.</li>
		<li>After 2 weeks, differentiate cells further into astrocytes: when cells are nearly confluent, change media to commercially available astrocyte media, change media every second day. After about 7 days, cells start to express astrocyte markers (e.g., GFAP). If cells get 100% confluent during the differentiation protocol, split them in a 1:2 ratio in the presence of 10 &#181;M ROCK inhibitor Y27632.</li>
	</ol>
	</li>
</ol>

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>Astrocyte media</td>
			<td>ScienCell</td>
			<td>1801</td>
			<td></td>
		</tr>
		<tr>
			<td>B27</td>
			<td>LifeTechnologies</td>
			<td>17504-044</td>
			<td></td>
		</tr>
		<tr>
			<td>BDNF</td>
			<td>Peprotech</td>
			<td>450-02</td>
			<td></td>
		</tr>
		<tr>
			<td>cAMP</td>
			<td>Sigma</td>
			<td>A6885</td>
			<td></td>
		</tr>
		<tr>
			<td>DMEM</td>
			<td>LifeTechnologies</td>
			<td>41966-029</td>
			<td></td>
		</tr>
		<tr>
			<td>DMEM F12</td>
			<td>LifeTechnologies</td>
			<td>11320-033</td>
			<td></td>
		</tr>
		<tr>
			<td>DMSO</td>
			<td>Roth</td>
			<td>4720</td>
			<td></td>
		</tr>
		<tr>
			<td>DPBS</td>
			<td>LifeTechnologies</td>
			<td>14190-094</td>
			<td></td>
		</tr>
		<tr>
			<td>EGF</td>
			<td>Life Technologies</td>
			<td>PHG0313</td>
			<td></td>
		</tr>
		<tr>
			<td>FCS</td>
			<td>Biochrom AG</td>
			<td>50115</td>
			<td></td>
		</tr>
		<tr>
			<td>GDNF</td>
			<td>Peprotech</td>
			<td>450-10</td>
			<td></td>
		</tr>
		<tr>
			<td>Insulin</td>
			<td>Seralab</td>
			<td>GEM-700-112-P</td>
			<td></td>
		</tr>
		<tr>
			<td>L-Glutamine</td>
			<td>LifeTechnologies</td>
			<td>25030-024</td>
			<td></td>
		</tr>
		<tr>
			<td>Laminin</td>
			<td>Sigma</td>
			<td>L2020</td>
			<td></td>
		</tr>
		<tr>
			<td>N2</td>
			<td>LifeTechnologies</td>
			<td>17502-048</td>
			<td></td>
		</tr>
		<tr>
			<td>Neurobasal</td>
			<td>LifeTechnologies</td>
			<td>21103-049</td>
			<td></td>
		</tr>
		<tr>
			<td>Non-essential amino acids</td>
			<td>LifeTechnologies</td>
			<td>11140-050</td>
			<td></td>
		</tr>
		<tr>
			<td>Vitamin C</td>
			<td>Sigma</td>
			<td>A4544</td>
			<td></td>
		</tr>
		<tr>
			<td>&#946;-Mercaptoethanol</td>
			<td>LifeTechnologies</td>
			<td>21985023</td>
			<td></td>
		</tr>
	</tbody>
</table>

Source: Meyer, S., et al., Edenhofer, F. <a href="https://app-jove-com.remotexs.ntu.edu.sg/v/52831">Derivation of Adult Human Fibroblasts and their Direct Conversion into Expandable Neural Progenitor Cells.</a> J. Vis. Exp. (2015)
This video demonstrates the process for differentiating induced neural progenitor cells (iNPCs) into neurons and astrocytes using specialized media.

1. Differentiation of iNPCs

	Differentiation towards neuronal lineage&#8203;
	
		Culture cells on laminin-coated plates as described above. Change media ...

Take a culture of induced neural progenitor cells, or iNPCs, on an extracellular matrix protein-coated multi-well plate.
Replace the media with glial induction media and incubate. Growth factors and hormones in the media facilitate iNPC differentiation into glial precursor cells.
Change the media every other day for cell proliferation. Then, replace the media with astrocyte media and incubate.
Specific nutrients and growth factors in the media drive glial precursor cell differentiation into astrocytes.
Media changes every other day promote astrocyte maturation.

23 Views. Differenziazione delle cellule progenitrici neurali indotte in astrociti

Video: Differenziazione delle cellule progenitrici neurali indotte in astrociti - Experiment

Rapid Detection of Neurodevelopmental Phenotypes in Human Neural Precursor Cells (NPCs)

Human brain development proceeds through a series of precisely orchestrated processes, with earlier stages distinguished by proliferation, migration, and neurite outgrowth; and later stages characterized by axon/dendrite outgrowth and synapse formation. In neurodevelopmental disorders, often one or more of these processes are disrupted, leading to abnormalities in brain formation and function. With the advent of human induced pluripotent stem cell (hiPSC) technology, researchers now have an abundant supply of human cells that can be differentiated into virtually any cell type, including neurons. These cells can be used to study both normal brain development and disease pathogenesis. A number of protocols using hiPSCs to model neuropsychiatric disease use terminally differentiated neurons or use 3D culture systems termed organoids. While these methods have proven invaluable in studying human disease pathogenesis, there are some drawbacks. Differentiation of hiPSCs into neurons and generation of organoids are lengthy and costly processes that can impact the number of experiments and variables that can be assessed. In addition, while post-mitotic neurons and organoids allow the study of disease-related processes, including dendrite outgrowth and synaptogenesis, they preclude the study of earlier processes like proliferation and migration. In neurodevelopmental disorders, such as autism, abundant genetic and post-mortem evidence indicates defects in early developmental processes. Neural precursor cells (NPCs), a highly proliferative cell population, may be a suitable model in which to ask questions about ontogenetic processes and disease initiation. We now extend methodologies learned from studying development in mouse and rat cortical cultures to human NPCs. The use of NPCs allows us to investigate disease-related phenotypes and define how different variables (e.g., growth factors, drugs) impact developmental processes including proliferation, migration, and differentiation in only a few days. Ultimately, this toolset can be used in a reproducible and high-throughput manner to identify disease-specific mechanisms and phenotypes in neurodevelopmental disorders.

Rapid Detection of Neurodevelopmental Phenotypes in Human Neural Precursor Cells NPCs

Neurodevelopmental processes such as proliferation, migration, and neurite outgrowth are often perturbed in neuropsychiatric diseases. Thus, we present protocols to rapidly and reproducibly assess these neurodevelopmental processes in human iPSC-derived NPCs. These protocols also allow the assessment of the effects of relevant growth factors and therapeutics on NPC development.

Rilevamento rapido dei fenotipi di Neurodevelopmental in cellule precursori neurali umane (NPC)

Human brain development proceeds through a series of precisely orchestrated processes, with earlier stages distinguished by proliferation, migration, and ...

Ricerca

JoVE Journal

Biologia dello sviluppo

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Parkinson&#39;s disease (PD) is caused by degeneration of dopaminergic (DA) neurons at the substantia nigra pars compacta (SNpc) in the ventral mesencephalon (VM). Cell replacement therapy holds great promise for treatment of PD. Recently, induced neural stem cells (iNSCs) have emerged as a potential candidate for cell replacement therapy due to the reduced risk of tumor formation and the plasticity to give rise to region-specific neurons and glia. iNSCs can be reprogrammed from autologous somatic cellular sources, such as fibroblasts, peripheral blood mononuclear cells (PBMNCs) and various other types of cells. Compared with other types of somatic cells, PBMNCs are an appealing starter cell type because of the ease to access and expand in culture. Sendai virus (SeV), an RNA non-integrative virus, encoding reprogramming factors including human OCT3/4, SOX2, KLF4 and c-MYC, has a negative-sense, single-stranded, non-segmented genome that does not integrate into host genome, but only replicates in the cytoplasm of infected cells, offering an efficient and safe vehicle for reprogramming. In this study, we describe a protocol in which iNSCs are obtained by reprogramming PBMNCs, and differentiated into specialized VM DA neurons by a two-stage method. Then DA precursors are transplanted into unilaterally 6-hyroxydopamine (6-OHDA)-lesioned PD mouse models to evaluate the safety and efficacy for treatment of PD. This method provides a platform to investigate the functions and therapeutic effects of patient-specific DA neural cells in vitro and in vivo.

The protocol presents the reprogramming of peripheral blood mononuclear cells to induce neural stem cells by Sendai virus infection, differentiation of iNSCs into dopaminergic neurons, transplantation of DA precursors into the unilaterally-lesioned Parkinson&#39;s disease mouse models, and evaluation of the safety and efficacy of iNSC-derived DA precursors for PD treatment.

Generazione di cellule staminali neurali indotte da cellule mononucleari periferiche e differenziazione verso i precursori dei neuroni dopaminergici per gli studi di trapianto

Parkinson&#39;s disease (PD) is caused by degeneration of dopaminergic (DA) neurons at the substantia nigra pars compacta (SNpc) in the ventral ...

High-Content Screening Differentiation and Maturation Analysis of Fetal and Adult Neural Stem Cell-Derived Oligodendrocyte Precursor Cell Cultures

The main hurdle in developing drug screening techniques for assessing the efficacy of therapeutic strategies in complex diseases is striking a balance between in vitro simplification and recreating the complex in vivo environment, along with the main aim, shared by all screening strategies, of obtaining robust and reliable data, highly predictive for in vivo translation.
In the field of demyelinating diseases, the majority of drug screening strategies are based on immortalized cell lines or pure cultures of isolated primary oligodendrocyte precursor cells (OPCs) from newborn animals, leading to strong biases due to the lack of age-related differences and of any real pathological condition or complexity.
Here we show the setup of an in vitro system aimed at modeling the physiological differentiation/maturation of neural stem cell (NSC)-derived OPCs, easily manipulated to mimic pathological conditions typical of demyelinating diseases. Moreover, the method includes isolation from fetal and adult brains, giving a system which dynamically differentiates from OPCs to mature oligodendrocytes (OLs) in a spontaneous co-culture which also includes astrocytes. This model physiologically resembles the thyroid hormone-mediated myelination and myelin repair process, allowing the addition of pathological interferents which model disease mechanisms. We show how to mimic the two main components of demyelinating diseases (i.e., hypoxia/ischemia and inflammation), recreating their effect on developmental myelination and adult myelin repair and taking all the cell components of the system into account throughout, while focusing on differentiating OPCs.
This spontaneous mixed model, coupled with cell-based high-content screening technologies, allows the development of a robust and reliable drug screening system for therapeutic strategies aimed at combating the pathological processes involved in demyelination and at inducing remyelination.

We describe the production of mixed cultures of astrocytes and oligodendrocyte precursor cells derived from fetal or adult neural stem cells differentiating into mature oligodendrocytes, and in vitro modeling of noxious stimuli. The coupling with a cell-based high-content screening technique builds a reliable and robust drug screening system.

Selezione ad alto contenuto di differenziazione e analisi della maturazione di colture cellulari precursori di oligodendrociti derivati da cellule staminali neurali fetali e adulte

The main hurdle in developing drug screening techniques for assessing the efficacy of therapeutic strategies in complex diseases is striking a balance ...

Differentiating Induced Neural Progenitor Cells into Astrocytes

Trascrizione

Differentiating Induced Neural Progenitor Cells into Astrocytes